HC Wainwright & Co. Maintains Buy on BridgeBio Oncology, Raises Price Target to $29
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and raises the price target from $27 to $29.
HC Wainwright & Co. analyst Robert Burns maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and raises the price target from $27 to $29.